Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R H Wilson

Showing results (171-180 of 176) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 176 results.
British Journal of Cancer|March 20, 2014
A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancerR M Glasspool, R Brown, M E Gore, et al.
European Journal of Cancer (Oxford, England : 1990)|September 10, 2018
An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumoursH-T Arkenau, A Italiano, G Mak, et al.
Proceedings. Biological Sciences|February 22, 1997
Enigmatic phylogeny of skuas (Aves:Stercorariidae)B L Cohen, A J Baker, K Blechschmidt, et al.
JAMA|October 12, 2000
Efficacy of 3 commonly used hearing aid circuits: A crossover trial. NIDCD/VA Hearing Aid Clinical Trial GroupV D Larson, D W Williams, W G Henderson, et al.
British Journal of Cancer|April 19, 2014
A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine?T S Maughan, A M Meade, R A Adams, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 18, 2018
Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancerB Basu, M G Krebs, R Sundar, et al.
Pageof 18

Showing results (171-180 of 176) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 176 results.
British Journal of Cancer|March 20, 2014
A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancerR M Glasspool, R Brown, M E Gore, et al.
European Journal of Cancer (Oxford, England : 1990)|September 10, 2018
An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumoursH-T Arkenau, A Italiano, G Mak, et al.
Proceedings. Biological Sciences|February 22, 1997
Enigmatic phylogeny of skuas (Aves:Stercorariidae)B L Cohen, A J Baker, K Blechschmidt, et al.
JAMA|October 12, 2000
Efficacy of 3 commonly used hearing aid circuits: A crossover trial. NIDCD/VA Hearing Aid Clinical Trial GroupV D Larson, D W Williams, W G Henderson, et al.
British Journal of Cancer|April 19, 2014
A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine?T S Maughan, A M Meade, R A Adams, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 18, 2018
Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancerB Basu, M G Krebs, R Sundar, et al.
Pageof 18